Laboratorios Farmaceuticos Rovi ( (ES:ROVI) ) has shared an update.
Laboratorios Farmacéuticos Rovi, S.A. has announced a new remuneration policy for its directors for the years 2025 to 2027, emphasizing principles such as moderation, alignment with market practices, and proportionality. The policy aims to attract and retain directors by aligning their remuneration with long-term company interests, promoting non-discrimination, and ensuring transparency and simplicity in corporate governance, which could enhance stakeholder confidence and support the company’s strategic objectives.
More about Laboratorios Farmaceuticos Rovi
Laboratorios Farmacéuticos Rovi, S.A. operates in the pharmaceutical industry, focusing on the development, production, and marketing of pharmaceutical products. The company is known for its commitment to innovation and quality in healthcare solutions, serving both domestic and international markets.
YTD Price Performance: -12.66%
Average Trading Volume: 3,521
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €2.77B
Find detailed analytics on ROVI stock on TipRanks’ Stock Analysis page.